Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly

Bodh I JugduttDivision of Cardiology, Department of Medicine, University of Alberta and Hospital, Edmonton, CanadaAbstract: Elderly patients (age≥65 years) with hypertension are at high risk for vascular complications, especially when diabetes is present. Antihypertensive drugs that inhibit t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Bodh I Jugdutt
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Elderly hypertension telmisartan angiotensin II type 1 receptor blocker peroxisome proliferator-activated receptor-gamma diabetes vascular risk Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/639d648d7b574749b16b4106bb81af14
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:639d648d7b574749b16b4106bb81af14
record_format	dspace
spelling	oai:doaj.org-article:639d648d7b574749b16b4106bb81af142021-12-02T08:30:46ZClinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly1178-1998https://doaj.org/article/639d648d7b574749b16b4106bb81af142010-12-01T00:00:00Zhttps://www.dovepress.com/clinical-effectiveness-of-telmisartan-alone-or-in-combination-therapy--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Bodh I JugduttDivision of Cardiology, Department of Medicine, University of Alberta and Hospital, Edmonton, CanadaAbstract: Elderly patients (age≥65 years) with hypertension are at high risk for vascular complications, especially when diabetes is present. Antihypertensive drugs that inhibit the renin-angiotensin system have been shown to be effective for controlling blood pressure in adult and elderly patients. Importantly, renin-angiotensin system inhibitors were shown to have benefits beyond their classic cardioprotective and vasculoprotective effects, including reducing the risk of new-onset diabetes and associated cardiovascular effects. The discovery that the renin-angiotensin system inhibitor and angiotensin II type 1 (AT1) receptor blocker (ARB), telmisartan, can selectively activate the peroxisome proliferator-activated receptor-γ (PPARγ, an established antidiabetic drug target) provides the unique opportunity to prevent and treat cardiovascular complications in high-risk elderly patients with hypertension and new-onset diabetes. Two large clinical trials, ONTARGET (Ongoing Telmisartan Alone in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized AssessmeNt Study in ACE-I iNtolerant subjects with cardiovascular disease) have assessed the cardioprotective and antidiabetic effects of telmisartan. The collective data suggest that telmisartan is a promising drug for controlling hypertension and reducing vascular risk in high-risk elderly patients with new-onset diabetes.Keywords: elderly, hypertension, telmisartan, angiotensin II type 1 receptor blocker, peroxisome proliferator-activated receptor-γ, diabetes, vascular riskBodh I JugduttDove Medical PressarticleElderlyhypertensiontelmisartanangiotensin II type 1 receptor blockerperoxisome proliferator-activated receptor-gammadiabetesvascular riskGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 403-416 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Elderly hypertension telmisartan angiotensin II type 1 receptor blocker peroxisome proliferator-activated receptor-gamma diabetes vascular risk Geriatrics RC952-954.6
spellingShingle	Elderly hypertension telmisartan angiotensin II type 1 receptor blocker peroxisome proliferator-activated receptor-gamma diabetes vascular risk Geriatrics RC952-954.6 Bodh I Jugdutt Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
description	Bodh I JugduttDivision of Cardiology, Department of Medicine, University of Alberta and Hospital, Edmonton, CanadaAbstract: Elderly patients (age≥65 years) with hypertension are at high risk for vascular complications, especially when diabetes is present. Antihypertensive drugs that inhibit the renin-angiotensin system have been shown to be effective for controlling blood pressure in adult and elderly patients. Importantly, renin-angiotensin system inhibitors were shown to have benefits beyond their classic cardioprotective and vasculoprotective effects, including reducing the risk of new-onset diabetes and associated cardiovascular effects. The discovery that the renin-angiotensin system inhibitor and angiotensin II type 1 (AT1) receptor blocker (ARB), telmisartan, can selectively activate the peroxisome proliferator-activated receptor-γ (PPARγ, an established antidiabetic drug target) provides the unique opportunity to prevent and treat cardiovascular complications in high-risk elderly patients with hypertension and new-onset diabetes. Two large clinical trials, ONTARGET (Ongoing Telmisartan Alone in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized AssessmeNt Study in ACE-I iNtolerant subjects with cardiovascular disease) have assessed the cardioprotective and antidiabetic effects of telmisartan. The collective data suggest that telmisartan is a promising drug for controlling hypertension and reducing vascular risk in high-risk elderly patients with new-onset diabetes.Keywords: elderly, hypertension, telmisartan, angiotensin II type 1 receptor blocker, peroxisome proliferator-activated receptor-γ, diabetes, vascular risk
format	article
author	Bodh I Jugdutt
author_facet	Bodh I Jugdutt
author_sort	Bodh I Jugdutt
title	Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
title_short	Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
title_full	Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
title_fullStr	Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
title_full_unstemmed	Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
title_sort	clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/639d648d7b574749b16b4106bb81af14
work_keys_str_mv	AT bodhijugdutt clinicaleffectivenessoftelmisartanaloneorincombinationtherapyforcontrollingbloodpressureandvascularriskintheelderly
_version_	1718398489399918592

Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly

Ejemplares similares